ClinicalTrials.gg
CompletedNCT00633217Updated Dec 8, 2016Results posted

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

A Phase 4 interventional study of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg and Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 16 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-12-08.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.

Enrollment
86th of 236
247 · median 101
Started
2008
with 21 others
Phase 4
38 of 276
none open now
Registered
56th of 276
by date

Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 86th largest by enrollment of the 236 interventional ones that give a count, is one of 22 that started in 2008, is one of 38 in phase 4, and was the 56th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of the FSC HFA MDI in subjects with COPD. The dose of FSC HFA MDI to be evaluated corresponds to the dose of FSC DISKUS (250/50mcg twice-daily) that is indicated for the treatment of COPD associated with chronic bronchitis in the US. This study will last up to approximately 15 weeks, and subjects will visit the clinic 5 times. Subjects will be given breathing tests and will record their peak expiratory flow measurements daily on diary cards. All study related medicines and medical examinations will be provided at no cost. The FSC HFA MDI used in this study has been approved by FDA for use in asthma while the FSC 250/50mcg DISKUS has been approved for use in asthma and COPD.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • DISKUS
  • Salmeterol
  • Fluticasone Propionate
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Hydroflouroalkane
  • COPD
  • HFA MDI
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible for enrollment in the study must meet all of the following criteria:

  • Signed and dated written obtained from the subject and/or subject's legally acceptable representative prior to study participation.
  • Males or females ≥ 40 years of age.

A female is eligible to participate in this study if she is of:

  1. non- (i.e., physiologically incapable of becoming pregnant, including any female who is [i.e., >1 year without menses in the absence of hormone replacement therapy]); or,
  2. child-bearing potential, has a negative pregnancy test (urine) at screen, and one of the following applies:

    • Abstinence from intercourse, or,
    • Male partner was sterile prior to the female subject's entry into the study, or,
    • Use of implants of levonorgestrel; or,
    • Injectable progesterone; or,
    • Oral (combined or progesterone only), contraceptive patch, vaginal ring; or,
    • Any intrauterine device (IUD) with published data showing that the highest expected failure rate is less than 1% per year (e.g., Paragard), or,
    • Double barrier technique simultaneously using two of the following: spermicide, male condom, diaphragm, or female condom

      • An established clinical history of (including chronic bronchitis and/or emphysema) in accordance with the following definition by the American Thoracic Society:

COPD is a preventable and treatable disease state characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences [Celli, 2004].

  • A post-albuterol /FVC ratio of ≤ 0.70
  • A post-albuterol FEV1 ≥ 0.70L and ≤ 70% of predicted normal OR a post-albuterol FEV1 of ≤ 0.70L and ≥40% of predicted normal but still ≤70% of predicted normal based on NHANES III reference values [Hankinson, 1999].
  • Current or previous smokers with a cigarette smoking history of ≥ 10 pack-years. [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 10 pack-years is equal to 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years]. Former-smokers are defined as subjects who have discontinued smoking for ≥ 6 months prior to Visit 1. Subjects who decide to stop smoking at Visit 1 will not be eligible for participation in the study.

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

  • A current diagnosis of asthma.
  • Any and uncontrolled disease, including but not limited to the following: neurological, psychiatric, renal, immunological, endocrine/metabolic (including uncontrolled diabetes, hypokalemia or thyroid disease), cardiovascular, neuromuscular, hepatic, gastric, or hematological abnormalities, or peripheral vascular disease. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would affect the efficacy analysis if the disease/condition exacerbated during the study.
  • A respiratory diagnosis other than (e.g., lung cancer, bronchiectasis, sarcoidosis, tuberculosis, lung fibrosis), including subjects with a diagnosis of alpha-1-antitrypsin deficiency. Allergic rhinitis is not exclusionary.
  • An abnormal and clinically significant chest x-ray or computed tomography (CT) scan not believed to be due to the presence of COPD. A chest x-ray must be taken if the subject has not had one within 6 months of Visit 1.
  • An abnormal and clinically significant 12-lead (ECG). For the purposes of this study, an abnormal ECG is defined as a 12-lead tracing which is interpreted with (but not limited to) any of the following:

    • Myocardial ischemia
    • Clinically significant conduction abnormalities (e.g., left bundle branch block, Wolff-Parkinson-White syndrome)
    • Clinically significant arrhythmias (e.g., atrial fibrillation, ventricular tachycardia) The study investigator will determine the clinical significance of any ECG abnormality and determine if a subject is precluded from entering the study.
  • Previously diagnosed cancer unless it is in complete clinical remission (no evidence of any tumor burden) at Visit 1. Localized carcinomas of the skin that have been resected for cure are not considered exclusionary.
  • Any immediate or delayed to any beta-agonist, sympathomimetic drug, or intranasal, inhaled, or oral including any components of the formulations (e.g. lactose or milk protein).
  • Initiation of systemic beta-blocker medications within 30 days of Visit 1.
  • Use of products containing the protease inhibitor ritonavir (Norvir, Kaletra).
  • Use of the following medications within the defined times prior to Visit 1:

Medication (Exclusion Prior to Visit 1) Short-acting beta-agonists (e.g., albuterol) (6 hours) Ipratropium (6 hours) Ipratropium/albuterol combination product (6 hours) Oral beta-agonists (48 hours) Salmeterol and formoterol (48 hours) Theophylline preparations (48 hours) Tiotropium (48 hours) Long-acting beta-agonist/inhaled corticosteroid combination products (e.g., ADVAIR™ or Symbicort) (30 days) Inhaled corticosteroids (30 days) Oral or parenteral corticosteroids (30 days) Any drug (30 days)

  • Lung resection surgery (e.g., lung volume reduction surgery, or lobectomy) within 1 year of Visit 1.
  • A COPD exacerbation and/or infection of the upper or lower respiratory tract requiring treatment with systemic (oral or parenteral) corticosteroids and/or antibiotics that has not resolved within 30 days of Visit 1
  • A COPD exacerbation that resulted in hospitalization that has not resolved within 3 months of Visit 1.
  • Use of nocturnal positive pressure [e.g., continuous positive airway pressure or bi-level positive airway pressure].
  • A (BMI) of ≥ 40kg/m².
  • Subject is a study investigator, sub-investigator, study coordinator, or employee of a participating investigator or immediate family members of the aforementioned.
  • Any intellectual deficiency including illiteracy, history of substance abuse in the two years prior to Visit 1 (including drug and alcohol), or other conditions, which will limit the validity of to participate in the study.
  • Supplemental oxygen, with the following exceptions:

    • Use at high altitude (> 5000 feet) provided subject does not require a flow rate of > 2 L/minute
    • Use for exertion provided subject does not require > 2 hours per day of oxygen and does not require a flow rate of > 2L/minute
    • Use for nocturnal therapy provided subject does not require a flow rate of > 2L/minute
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
247 participants (actual)

Study arms

  • Active comparator
    arm 1

    Drug: Fluticasone Propionate/Salmeterol DISKUS 250/50mcg

  • Experimental
    arm 2

    Drug: Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg

Interventions

  • DrugFluticasone Propionate/Salmeterol DISKUS 250/50mcg

    treatment drug

  • DrugFluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg

    treatment drug

    Also known as: Fluticasone Propionate/Salmeterol DISKUS 250/50mcg

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) 2 Hours Post-dose of Blinded Study Drug

    The primary efficacy analysis was mean change from baseline in 2-hour post-dose FEV1 compared between the two treatment groups at Endpoint. Change from baseline was calculated as the value at Endpoint minus the baseline value. FEV1, which is assessed using spirometry, is the maximal amount of air you can forcefully exhale in one second. Endpoint was defined as the last scheduled observation for 2 hour post-dose FEV1 during the 12-week treatment period.

    Time frame: 2 hours after administration of blinded study drug; Baseline through Week 12

Secondary outcomes

  1. Mean Change From Baseline in AM Pre-dose FEV1

    Change from baseline was calculated as the value at Endpoint minus the baseline value. AM pre-dose FEV1, which is assessed using spirometry, is the maximum amount of air you can forcefully exhale in one second prior to taking the morning dose of study drug. Endpoint was defined as the last scheduled observation for AM pre-dose FEV1 during the 12-week treatment period.

    Time frame: Measurement of FEV1 prior to study drug administration; Baseline through Week 12

  2. Mean Change From Baseline in Peak Expiratory Flow

    The peak expiratory flow is a measure of the amount of air that can be pushed through the airways in a single rapid exhalation. This is measured by a peak flow meter which is a hand held device. Change from baseline was calculated as the average value over Weeks 1-12 minus the baseline value.

    Time frame: Baseline through Week 12

07

Results

Posted Nov 26, 2009

Participant flow

Participant flow — Overall Study
MilestoneHFA MDI 230/42 mcg and Matching DISKUS PlaceboDISKUS 250/50 mcg and Matching HFA MDI Placebo
Started121126
Completed106103
Not completed1523
Withdrew: Adverse event59
Withdrew: Lack of efficacy02
Withdrew: Protocol violation37
Withdrew: Lost to follow-up22
Withdrew: Investigator discretion20
Withdrew: Withdrew consent33

Outcome measures

PrimaryMean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) 2 Hours Post-dose of Blinded Study Drug

The primary efficacy analysis was mean change from baseline in 2-hour post-dose FEV1 compared between the two treatment groups at Endpoint. Change from baseline was calculated as the value at Endpoint minus the baseline value. FEV1, which is assessed using spirometry, is the maximal amount of air you can forcefully exhale in one second. Endpoint was defined as the last scheduled observation for 2 hour post-dose FEV1 during the 12-week treatment period.

Time frame:
2 hours after administration of blinded study drug; Baseline through Week 12
Reported as:
Mean · milliliters (mL)
Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) 2 Hours Post-dose of Blinded Study Drug
milliliters (mL)HFA MDI 230/42 mcg and Matching DISKUS PlaceboDISKUS 250/50 mcg and Matching HFA MDI Placebo
Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) 2 Hours Post-dose of Blinded Study Drug155 ± 23.4150 ± 21.9
Statistical analysis
  • HFA MDI 230/42 mcg and Matching DISKUS Placebo vs DISKUS 250/50 mcg and Matching HFA MDI Placebo · ANCOVA · p = 0.021
SecondaryMean Change From Baseline in AM Pre-dose FEV1

Change from baseline was calculated as the value at Endpoint minus the baseline value. AM pre-dose FEV1, which is assessed using spirometry, is the maximum amount of air you can forcefully exhale in one second prior to taking the morning dose of study drug. Endpoint was defined as the last scheduled observation for AM pre-dose FEV1 during the 12-week treatment period.

Time frame:
Measurement of FEV1 prior to study drug administration; Baseline through Week 12
Reported as:
Mean · mL
Mean Change From Baseline in AM Pre-dose FEV1
mLHFA MDI 230/42 mcg and Matching DISKUS PlaceboDISKUS 250/50 mcg and Matching HFA MDI Placebo
Mean Change From Baseline in AM Pre-dose FEV174 ± 20.677 ± 20.5
SecondaryMean Change From Baseline in Peak Expiratory Flow

The peak expiratory flow is a measure of the amount of air that can be pushed through the airways in a single rapid exhalation. This is measured by a peak flow meter which is a hand held device. Change from baseline was calculated as the average value over Weeks 1-12 minus the baseline value.

Time frame:
Baseline through Week 12
Reported as:
Mean · Liters/minute (L/min)
Mean Change From Baseline in Peak Expiratory Flow
Liters/minute (L/min)HFA MDI 230/42 mcg and Matching DISKUS PlaceboDISKUS 250/50 mcg and Matching HFA MDI Placebo
Mean Change From Baseline in Peak Expiratory Flow21.8 ± 2.6618.7 ± 2.48

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HFA MDI 230/42 mcg and Matching DISKUS Placebo—6/121 (5%)27/121 (22.3%)
DISKUS 250/50 mcg and Matching HFA MDI Placebo—3/126 (2.4%)29/126 (23%)
Most frequent serious events
Most frequent serious events
EventHFA MDI 230/42 mcg and Matching DISKUS PlaceboDISKUS 250/50 mcg and Matching HFA MDI Placebo
Chronic Obstructive Pulmonary Disease ExacerbationRespiratory, thoracic and mediastinal disorders3/1212/126
Urinary Tract InfectionInfections and infestations2/1210/126
AppendicitisInfections and infestations1/1211/126
GastritisGastrointestinal disorders1/1210/126
ContusionInjury, poisoning and procedural complications1/1210/126
HypoglycaemiaMetabolism and nutrition disorders1/1210/126
Lumbar Spinal StenosisMusculoskeletal and connective tissue disorders1/1210/126
PneumoniaInfections and infestations0/1211/126
Most frequent other events
Most frequent other events
EventHFA MDI 230/42 mcg and Matching DISKUS PlaceboDISKUS 250/50 mcg and Matching HFA MDI Placebo
HeadacheNervous system disorders10/1218/126
NasopharyngitisInfections and infestations5/1218/126
SinusitisInfections and infestations3/1216/126
Oropharyngeal painRespiratory, thoracic and mediastinal disorders5/1212/126
CoughRespiratory, thoracic and mediastinal disorders4/1215/126

Baseline characteristics

Age, Continuous
Age, Continuous(years)HFA MDI 230/42 mcg and Matching DISKUS PlaceboDISKUS 250/50 mcg and Matching HFA MDI PlaceboTotal
Mean61.6 (40 to 84)63.4 (45 to 86)61.6 (40 to 86)
Gender
Gender(Participants)HFA MDI 230/42 mcg and Matching DISKUS PlaceboDISKUS 250/50 mcg and Matching HFA MDI PlaceboTotal
Female5560115
Male6666132
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)HFA MDI 230/42 mcg and Matching DISKUS PlaceboDISKUS 250/50 mcg and Matching HFA MDI PlaceboTotal
African American/African Heritage10919
White - White/Caucasian/European Heritage109117226
American Indian or Alaskan Native101
White - Arabic/North African Heritage101
08

Study locations

16 sites
  • GSK Investigational Site
    Jasper, Alabama 35501, United States
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Lafayette, Louisiana 70503, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70115, United States
  • GSK Investigational Site
    Sunset, Louisiana 70584, United States
  • GSK Investigational Site
    St. Charles, Missouri 63301, United States
  • GSK Investigational Site
    Elizabeth City, North Carolina 27909, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16508, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406-7108, United States
  • GSK Investigational Site
    Gaffney, South Carolina 29340, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Union, South Carolina 29309, United States
  • GSK Investigational Site
    Corsicana, Texas 75110, United States
  • GSK Investigational Site
    Richmond, Virginia 23229, United States
  • GSK Investigational Site
    Morgantown, West Virginia 26505, United States
09

References and documents

Publications

  • Koser A, Westerman J, Sharma S, Emmett A, Crater GD. Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary disease. Open Respir Med J. 2010 Oct 21;4:86-91. doi: 10.2174/1874306401004010086. PubMed 21253451 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2008
First posted
Mar 11, 2008
Start
Mar 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Nov 26, 2009
Last update
Dec 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00633217
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 11, 2008
Start date
Mar 2008
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Nov 26, 2009
Last update
Dec 8, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion